Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2006

Open Access 01-12-2006 | Research article

Screening of Tanzanian medicinal plants for anti-Candida activity

Authors: Deborah KB Runyoro, Mecky IN Matee, Olipa D Ngassapa, Cosam C Joseph, Zakaria H Mbwambo

Published in: BMC Complementary Medicine and Therapies | Issue 1/2006

Login to get access

Abstract

Background

Candida albicans has become resistant to the already limited, toxic and expensive anti-Candida agents available in the market. These factors necessitate the search for new anti-fungal agents.

Methods

Sixty-three plant extracts, from 56 Tanzanian plant species obtained through the literature and interviews with traditional healers, were evaluated for anti-Candida activity. Aqueous methanolic extracts were screened for anti-Candida activity by bioautography agar overlay method, using a standard strain of Candida albicans (ATCC 90028).

Results

Twenty- seven (48%) out of the 56 plants were found to be active. Extracts of the root barks of Albizia anthelmintica and Balanites aegyptiaca, and roots of Plectranthus barbatus showed strong activity.

Conclusion

The extracts that showed strong anti-Candida activity are worth of further investigation in order to isolate and identify the active compounds.
Appendix
Available only for authorised users
Literature
1.
Ghannoum MA: Future of antimycotic therapy. Dermatologic Therapy. 1997, 3: 104-11.
2.
Vazquez JA: Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials. 2000, 1: 47-59. 10.1310/T7A7-1E63-2KA0-JKWD.CrossRefPubMed
3.
Vazquez JA: Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy. 1999, 19: 76-87. 10.1592/phco.19.1.76.30509.CrossRefPubMed
4.
Anteyi KO, Thacher TD, Yohanna S, Idoko JI: Oral manifestations of HIV-AIDS in Nigerian patients. Int J STD AIDS. 2003, 14: 395-8. 10.1258/095646203765371286.CrossRefPubMed
5.
Edwards JE: Candida species. Mandell, Douglas and Bennett's principles and practice of infectious diseases. Edited by: Mandell GL, Bennett JE, Dolin R. 1995, New York: Churchill Livingstone, 2: 2289-2301. 4
6.
Krcmery V, Barnes AJ: Non-albicans Candida species causing fungaemia: Pathogenicity and antifungal resistance. J Hosp Infect. 2002, 50: 243-60. 10.1053/jhin.2001.1151.CrossRefPubMed
7.
Musial CE, Cockenii FR, Roberts GD: Fungal infections of the immunocompromised host. Clinical laboratory aspects. Clin Microbiol Rev. 1988, 1: 349-364.CrossRefPubMedPubMedCentral
8.
Marty F, Mylonakis E: Antifungal use in HIV infection. Expert Opin Pharmacother. 2002, 3: 91-102. 10.1517/14656566.3.2.91.CrossRefPubMed
9.
UNAIDS: Report on the Global AIDS epidemic. UNAIDS. 2004
10.
Mehta DK, Martin J, Jordan B, Macfarlane CR, Hashimi FT, Kouimtzi M, Ryan RSM, Shing T, Wagle SMS, Gallagher GP, (eds): British National Formulary. 2002, London, Pharmaceutical Press, 294-298. 43
11.
Feldmesser M: New and emerging antifungal agents: Impact on respiratory infections. Am J Respir Med. 2003, 2: 371-83.CrossRefPubMed
12.
Wong-Beringer A, Kriengkauykiat J: Systemic antifungal therapy: New options, new challenges. Pharmacotherapy. 2003, 23: 1441-62. 10.1592/phco.23.14.1441.31938.CrossRefPubMed
13.
Perea S, López-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, Calabrese D, Sanglard D, Patterson TF: Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains, displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2001, 45: 2676-2684. 10.1128/AAC.45.10.2676-2684.2001.CrossRefPubMedPubMedCentral
14.
Klepser ME: Antifungal resistance among Candida species. Pharmacotherapy. 2001, 21: 124S-132S. 10.1592/phco.21.12.124S.34511.CrossRefPubMed
15.
Pelletier R, Loranger L, Marcote H, De Carolis E: Variconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol. 2002, 51: 479-83.CrossRefPubMed
16.
Khan ZU, Chandy R, Metwali KE: Candida albicans strain carriage in patients and nursing staff of an intensive care unit: A study of morphotypes and resistotypes. Mycoses. 2003, 46: 476-86. 10.1046/j.0933-7407.2003.00929.x.CrossRef
17.
Debruyne D: Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997, 33: 52-77.CrossRefPubMed
18.
Lachoria L, Jain PC, Agrawal SC: Activity of some plant extracts against dermatophytes. Hindustan Antibiot Bull. 1999, 41: 17-21.PubMed
19.
Rahalison L, Hamburger M, Hostettmann K, Monod M, Frenk E: A bioautographic agar overlay method for the detection of anti-fungal compounds from higher plants. Phytochem Anal. 1991, 2: 199-203.CrossRef
20.
Sawhney AN, Khan MR, Ndaalio G, Nkunya MHH, Wever SH: Studies on the rationale of African Traditional medicine. Part III. Preliminary screening of medicinal plants for antifungal activity. Pak J Sci Ind Res. 1978, 21: 193-196.
21.
Khan MN, Ngassapa O, Matee MIN: Antimicrobial activity of Tanzanian chewing sticks against oral pathogenic microbes. Pharmaceutical Biol. 2000, 38: 235-240.CrossRef
22.
Laskaris G, Hadjivassiliou M, Stratigos J: Oral signs and symptoms in 160 Greek HIV-infected patients. J Oral Path Med. 1992, 21: 120-3.CrossRef
23.
Connolly GM, Hawkins D, Harcourt-Webster JN, Parsons PA, Husain OA, Gazzard BG: Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. BMJ. 1989, 30: 1033-1039.
24.
Namkinga LA, Matee MIN, Kivaisi AK, Moshiro C: Prevalence and risk factors for vaginal candidiasis among women seeking primary care for genital infections in Dar es Salaam, Tanzania. E Afr Med J. 2005, 82: 138-143.
25.
Evans WC: Trease and Evans' Pharmacognosy. 1989, Bailliere Tindall, London, Philadelphia, Toronto, Marrickville, Tokyo, Thirteenth
26.
Gundidza M: Screening of extracts from Zimbabwean higher plants II: Antifungal properties. Fitoterapia. 1986, 57: 111-113.
27.
Boily Y, Van Puyvelde L: Screening of medicinal plants of Rwanda (Central Africa) for antimicrobial activity. J Ethnopharmacol. 1986, 16: 1-13. 10.1016/0378-8741(86)90062-0.CrossRefPubMed
28.
Almagboul AZ, Bashir AK, Karim A, Salih M, Farouk A, Khalid SA: Antimicrobial activity of certain Sudanese plants used in folkloric medicine. Screening for antifungal activity (VI). Fitoterapia. 1988, 59: 393-396.
29.
Taniguchi M, Chapya A, Kubo I, Nakanishi K: Screening of East African plants for antimicrobial activity. Chem Pharm Bull. 1978, 26: 2910-2913.CrossRef
30.
Desta B: Ethiopian traditional herbal drugs. Part II: Antimicrobial activity of 63 medicinal plants. J of Ethnopharmacol. 1993, 39: 129-139. 10.1016/0378-8741(93)90028-4.CrossRef
31.
Al-Bagieh NH, Idowu A, Salako NO: Effect of aqueous extract of miswak on the in vitro growth of Candida albicans. Microbios. 1994, 80: 107-113.PubMed
32.
Saeed A, Ibrahim N, Bashand YS, El-Gengaihi S: Saponins of Balanites aegyptiaca Del fruits and biological evaluation. Bull Fac Pharm Cairo Univ. 1995, 33: 105-109.
33.
Fabry W, Okemo P, Ansorg R: Fungistatic and fungicidal activity of East African medicinal plants. Mycoses. 1996, 39: 67-70.CrossRefPubMed
34.
Dhawan BN, Patnaik GK, Rastogi RP, Singh KK, Tandon JS: Screening of Indian plants for biological activity. VI. Indian J Exp Biol. 1977, 15: 208-219.PubMed
35.
Abreu PM, Martins ES, Kayser O, Bindseil KU, Siems K, Seemann A, Frevert J: Antimicrobial, antitumor and antileishmania screening of medicinal plants from Guinea-Bissau. Phytomedicine. 1999, 6: 187-195.CrossRefPubMed
36.
Carpani G, Orsini F, Sisti M, Verrota L: Soponins from Albizia anthelmintica. Phytochemistry. 1989, 28: 863-866. 10.1016/0031-9422(89)80131-1.CrossRef
37.
Tschesche R, Kammerer FJ: On triterpenes XXVII. The structure of musennin and deglucomusennin. (Über Triterpene XXVII Die strukturvon musennin und desglucomusennin). Justus Liebigs Ann Chem. 1969, 724: 183-193.CrossRef
38.
Farid H, Haslinger E, Kunert O, Wegner C, Hamburger M: New steroidal glycosides from Balanites aegyptiaca. Helv Chim Acta. 2002, 85: 1019-1026. 10.1002/1522-2675(200204)85:4<1019::AID-HLCA1019>3.0.CO;2-S.CrossRef
39.
Wagner H, Bladt S, Zygainski EM: Plant Drug Analysis. A thin Layer Chromatography Atlas. 1984, Springer Verlag, Berlin, Heidelberg, New York, Tokyo
40.
Gaudin O, Vacherat R: Rotenone and the ichthyotoxic power in some plants of the French Sudan. Bull Sci Pharmacol. 1938, 45: 385-394.
41.
Mazzanti G, Erspamer GF, Mugne Y, Piccinelli D: Occurrence of Histamine and related imidazole compounds in extracts from root and trunk bark of Albizia adianthifolia, Albizia anthelmintica and Albizia julibrissin. Fitoterapia. 1983, 54: 275-280.
42.
Abdel-Mogib M, Albar HA, Battrjee SM: Review. Chemistry of the Genus Plectranthus. Molecules. 2002, 7: 271-301.CrossRef
43.
Camara CC, Nascimento NR, Macedo-Filho CL, Almeida FB, Fonteles MC: Antispasmodic effect of the essential oil of Plectranthus barbatus and some major constituents on the guinea pig ileum. Planta Medica. 2003, 69: 1080-1085. 10.1055/s-2003-45186.CrossRefPubMed
Metadata
Title
Screening of Tanzanian medicinal plants for anti-Candida activity
Authors
Deborah KB Runyoro
Mecky IN Matee
Olipa D Ngassapa
Cosam C Joseph
Zakaria H Mbwambo
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2006
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-6-11

Other articles of this Issue 1/2006

BMC Complementary Medicine and Therapies 1/2006 Go to the issue

Research article

Ethnopharmacological evaluation of radal (leaves of Lomatia hirsuta) and isolation of 2-methoxyjuglone

Research article

Evaluating complementary and alternative medicine interventions: in search of appropriate patient-centered outcome measures

Research article

The chrondoprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1β

Research article

Evaluation of wound healing activity of Allamanda cathartica. L. and Laurus nobilis. L. extracts on rats

Research article

Cardioprotective effect of the Hibiscus rosa sinensis flowers in an oxidative stress model of myocardial ischemic reperfusion injury in rat

Research article

New Canadian natural health product regulations: a qualitative study of how CAM practitioners perceive they will be impacted